DGAP-News: BB Biotech statement on MiFID II
30.10.2017 – 17:53
DGAP-News: BB BIOTECH AG / Key word(s): Miscellaneous BB Biotech statement on MiFID II (news with additional features) 30.10.2017 / 17:40 The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Media Release of October 30, 2017 BB Biotech statement on MiFID II Under the European Union's new Markets in Financial Instruments Directive MiFID II that enters into effect at the beginning of 2018, financial services providers will be required to provide clients with a transparent disclosure of research costs and state how those costs will be absorbed. Bellevue Asset Management, the company retained by BB Biotech, will absorb the costs incurred for research and will not pass them onto its shareholders. For further information: Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Tanja Chicherio, Tel. +41 44 267 67 07,tch@bellevue.ch www.bbbiotech.com Company profile BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science. -------------------------------------------------------------------------------- Additional features: Document:http://n.eqs.com/c/fncls.ssp?u=WCDJYRBCMA Document title: Media release -------------------------------------------------------------------------------- 30.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -------------------------------------------------------------------------------- Language: English Company: BB BIOTECH AG Schwertstrasse 6 8200 Schaffhausen Switzerland Phone: +41 52 624 08 45 E-mail: info@bbbiotech.com Internet: www.bbbiotech.ch ISIN: CH0038389992 WKN: A0NFN3 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX End of News DGAP News Service -------------------------------------------------------------------------------- 623749 30.10.2017